New Research Shows Tumor Reduction Without Weight Loss Researchers tested whether low-dose Retatrutide (Reta) (a triple incretin agonist) could slow cancer growth independent of weight loss, using a mouse model of pancreatic ductal adenocarcinoma (PDAC) in diet-induced obese mice
There is no required recovery period, making it easy to schedule around a busy lifestyle
GLP-1 receptor agonists are a class of medications that work by mimicking the bodys natural glucagon-like peptide-1 hormone
Peptide solutions that drain from the nasal cavity to the oropharynx can produce a bitter or unpleasant taste
24,29 Through this receptor, GLP-1 leads to an increase of cAMP levels that thereafter activates protein kinase A (PKA)
Even though clinical studies show significant weight loss with GLP-1 RAs, and their use in youth has surged, access and application remain uneven